Treatment with the Dipeptidyl Peptidase-4 Inhibitor Vildagliptin Improves Fasting Islet-Cell Function in Subjects with Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Abstract
Context: Dipeptidyl peptidase 4 (DPP-4) inhibitors are proposed to lower blood glucose in type 2 diabetes mellitus (T2DM) by prolonging the activity of the circulating incretins, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1). Consistent with this mechanism of action, DPP-4 inhibitors improve glucose tolerance after meals by increasing insulin and reducing glucagon levels in the plasma. However, DPP-4 inhibitors also reduce fasting blood glucose, an unexpected effect because circulating levels of active GIP and GLP-1 are low in the postabsorptive state. Objective: The objective of the study was to examine the effects of DPP-4 inhibition on fasting islet function. Design: We conducted a randomized, double-blind, placebo-controlled trial. Setting: The study was performed in General Clinical Research Centers at two University Hospitals. Subjects: Forty-one subjects with T2DM were treated with metformin or diet, having good glycemic control with glycosylated hemoglobin values of 6.2–7.5%. Intervention: Subjects were treated with vildagliptin (50 mg twice daily) or placebo for 3 months, followed by a 2-wk washout. Major Outcome Measure: We measured insulin secretion in response to iv glucose and arginine before and after treatment and after drug washout. Results: There were small and comparable reductions in glycosylated hemoglobin in both groups over 3 months. Vildagliptin increased fasting GLP-1 levels in subjects taking metformin, but not those managed with diet, and raised active GIP levels slightly. DPP-4 inhibitor treatment improved the acute insulin and C-peptide responses to glucose (50 and 100% respectively; P < 0.05) and increased the slope of the C-peptide response to glucose (33%; P = 0.023). Conclusion: Vildagliptin improves islet function in T2DM under fasting conditions. This suggests that DPP-4 inhibition has metabolic benefits in addition to enhancing meal-induced GLP-1 and GIP activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Following 32 days of daily treatment, cotadutide further improved postprandial glucose control and potentiated weight loss in subjects with T2D and chronic kidney disease, which was paralleled with a notable 51% reduction in the urinary albumin-to-creatinine ratio98.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [98]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“1% cross-reactivity with GIP[3–42], the product of DPP-4.”
BackgroundThe biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · cited 1×
“Studies in cultured -cells and rodent models have demonstrated effects of GLP-1 and GIP signaling on -cell replication, growth, and apoptosis, with an overall effect of increasing islet mass (6).”
BackgroundWeyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940 · cited 1×
“However, treatment caused a significant improvement of the acute insulin response to glucose, the sensitivity of insulin release to glucose, and maximal arginine-stimulated -cell secretion, measures of insulin secretion that are among the classic lesions of T2DM (32, 33).”
BackgroundSelf-citationQuantitative estimation of insulin sensitivity.
Bergman, R. N., Ider, Y. Z., Bowden, C. R., & Cobelli, C. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.236.6.e667 · Cited by 1,874 · cited 2×
“The disposition index (DI), a measure of insulin secretion corrected for the degree of SI, was calculated as the product of AIRg and SI (21).”
MethodDipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides
Mentlein, R. (1999) · Regulatory Peptides · doi:10.1016/s0167-0115(99)00089-0 · Cited by 1,272 · cited 1×
“DPP-4 is a widely expressed serine protease with particularly high levels of activity in the liver, kidney, and intestine (3, 4).”
BackgroundKieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124 · cited 1×
“DPP-4 rapidly removes the two N-terminal amino acids from GIP and GLP-1 after their release from intestinal endocrine cells, abolishing their insulinotropic activity (8, 9).”
BackgroundVilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884 · cited 1×
“1% cross-reactivity with GIP[3–42], the product of DPP-4.”
BackgroundAschner, P., Kipnes, M. S., Lunceford, J. K., Sanchez, M., Mickel, C., Williams-Herman, D. E., & for the Sitagliptin Study 021 Group (2006) · Diabetes Care · doi:10.2337/dc06-0703 · Cited by 880
Ahrén, B., Landin-Olsson, M., Jansson, P.-A., Svensson, M., Holmes, D., & Schweizer, A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031907 · Cited by 710
The Importance of β-Cell Failure in the Development and Progression of Type 2 Diabetes
Kahn, S. E. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.9.7713 · Cited by 660
Cited by
Röhrborn, D. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00386 · Cited by 440
Matthews, D. R., Dejager, S., Ahren, B., Fonseca, V., Ferrannini, E., Couturier, A., Foley, J. E., & Zinman, B. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01233.x · Cited by 199
Self-citationGlycaemic control in type 2 diabetes: Targets and new therapies
Tahrani, A. A., Piya, M. K., Kennedy, A., & Barnett, A. H. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.11.001 · Cited by 190
Balakumar, M., Prabhu, D., Sathishkumar, C., Prabu, P., Rokana, N., Kumar, R., Raghavan, S., Soundarajan, A., Grover, S., Batish, V. K., et al. (2018) · European Journal of Nutrition · doi:10.1007/s00394-016-1317-7 · Cited by 187
Dipeptydil peptidase-4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials
Monami, M., Iacomelli, I., Marchionni, N., & Mannucci, E. (2010) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2009.03.015 · Cited by 174
Mechanisms of action of the dipeptidyl peptidase‐4 inhibitor vildagliptin in humans
Ahrén, B., Schweizer, A., Dejager, S., Villhauer, E. B., Dunning, B. E., & Foley, J. E. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01414.x · Cited by 171
Self-citationAdvances in the Treatment of Type 2 Diabetes Mellitus
Israili, Z. H. (2011) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181afbf51 · Cited by 165
“Vildagliptin improves islet-cell function by increasing both a- and b-cell responsiveness to glucose.(220,255) Improvement in b-cell function (assessed by increase in HOMA-b), insulin sensitivity (reduction in HOMAinsulin resistance), postprandial insulin secretion, and a reduction in postprandial glucagon secretion w…”
BackgroundEffect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes
Tremblay, A. J., Lamarche, B., Deacon, C. F., Weisnagel, S. J., & Couture, P. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01362.x · Cited by 160
Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Tan, Q., Akindehin, S. E., Orsso, C. E., Waldner, R. C., DiMarchi, R. D., Müller, T. D., & Haqq, A. M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.838410 · Cited by 146
Zhao, Y., Yang, L., Xiang, Y., Liu, L., Huang, G., Long, Z., Li, X., Leslie, R. D., Wang, X., & Zhou, Z. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3633 · Cited by 128
“Existing studies indicate that DPP-4 inhibitors have the potential to protect -cell function (3, 4) in patients with type 2 diabetes as well as in a mouse model of autoimmune diabetes (7).”
BackgroundExercise therapy in Type 2 diabetes
Praet, S. F. E., & van Loon, L. J. C. (2009) · Acta Diabetologica · doi:10.1007/s00592-009-0129-0 · Cited by 128
“These incretin mimicking drugs have been shown to improve islet-cell function, and both fasting and post-prandial glycemic control [32–36].”
BackgroundTransforming obesity: The advancement of multi-receptor drugs
Kusminski, C. M., Perez-Tilve, D., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Scherer, P. E. (2024) · Cell · doi:10.1016/j.cell.2024.06.003 · Cited by 126
Clinical Pharmacokinetics and Pharmacodynamics of Vildagliptin
He, Y. (2012) · Clinical Pharmacokinetics · doi:10.2165/11598080-000000000-00000 · Cited by 142
“Since GLP-1 has been shown to suppress glucagon release in a glucose-dependent manner,([118]) the effects of vildagliptin on fasting and postprandial glucagon levels were assessed in several studies in patients with T2DM.([42,51,110-113,121]) In an initial pharmacokinetic and pharmacodynamic dose-response study in pat…”
BackgroundMethodSelf-citationCai, H., Liu, F., Zuo, P., Huang, G., Song, Z., Wang, T., Lu, H., Guo, F., Han, C., & Sun, G. (2015) · Medicinal Chemistry · doi:10.2174/1573406410666141110153858 · Cited by 130
Probiotics supplementation and insulin resistance: A systematic review
Salles, B. I. M., Cioffi, D., & Ferreira, S. R. G. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00603-6 · Cited by 114
Aaboe, K., Knop, F. K., Vilsbøll, T., Deacon, C. F., Holst, J. J., Madsbad, S., & Krarup, T. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01167.x · Cited by 112
“[45] examining vildagliptin, confirming our results as a class effect.”
ResultDo we know the true mechanism of action of the DPP ‐4 inhibitors?
Andersen, E. S., Deacon, C. F., & Holst, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13018 · Cited by 107
“fasting subjects, when incretin hormone concentrations in the peripheral circulation are very low.(18) The explanation for this might be”
BackgroundTargeting β-Cell Function Early in the Course of Therapy for Type 2 Diabetes Mellitus
Leahy, J. L., Hirsch, I. B., Peterson, K. A., & Schneider, D. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0668 · Cited by 108
Mechanisms for the Antihyperglycemic Effect of Sitagliptin in Patients with Type 2 Diabetes
Muscelli, E., Casolaro, A., Gastaldelli, A., Mari, A., Seghieri, G., Astiarraga, B., Chen, Y., Alba, M., Holst, J., & Ferrannini, E. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1205 · Cited by 104
“Similar results have been observed with sitagliptin and vildagliptin using the iv glucose tolerance test-minimal model, MTT, or the hyperglycemic clamp technique (13, 33, 34).”
BackgroundResultLatent Autoimmune Diabetes in Adults: A Review on Clinical Implications and Management
Pieralice, S., & Pozzilli, P. (2018) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2018.0190 · Cited by 102
“org DPP-4 inhibitors DPP-4 inhibitors have been widely investigated in T2DM, providing evidence of a protective role on islet β-cells [69-71].”
BackgroundLatent Autoimmune Diabetes in Adults: Current Status and New Horizons
Pozzilli, P., & Pieralice, S. (2018) · Endocrinology and Metabolism · doi:10.3803/enm.2018.33.2.147 · Cited by 131
Aulinger, B. A., Bedorf, A., Kutscherauer, G., de Heer, J., Holst, J. J., Göke, B., & Schirra, J. (2014) · Diabetes · doi:10.2337/db13-1455 · Cited by 92
“Ex(9-39)acetate was purchased as a lyophilized sterile powder at pharmaceutical grade from Bachem (Clinalfa Products, Läufelfingen, Switzerland).”
BackgroundMethodInfluentialFoley, J. E., Bunck, M. C., Möller-Goede, D. L., Poelma, M., Nijpels, G., Eekhoff, E. M., Schweizer, A., Heine, R. J., & Diamant, M. (2011) · Diabetologia · doi:10.1007/s00125-011-2167-8 · Cited by 83
“A previous study with 50 mg vildagliptin twice daily [8] demonstrated that after 3 months there was a ~9% increase in the capacity for insulin secretion.”
BackgroundMethodSelf-citationGuerci, B., Monnier, L., Sérusclat, P., Petit, C., Valensi, P. E., Huet, D., Raccah, D., Colette, C., Quéré, S., & Dejager, S. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2012.06.001 · Cited by 82
Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus
Sesti, G., Avogaro, A., Belcastro, S., Bonora, B. M., Croci, M., Daniele, G., Dauriz, M., Dotta, F., Formichi, C., Frontoni, S., et al. (2019) · Acta Diabetologica · doi:10.1007/s00592-018-1271-3 · Cited by 94
van Genugten, R. E., van Raalte, D. H., & Diamant, M. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01473.x · Cited by 73
“Indeed, whether the beneficial effects that are observed in clinical trials up to 2 years remain after drug-wash-out, is still inconclusive (Table 1) since few studies reported off-drug values of β-cell function of which only one showed durable effects measured four to seven days after cessation of therapy [56], where…”
BackgroundResultÅhrén, B., & Foley, J. E. (2016) · Diabetologia · doi:10.1007/s00125-016-3899-2 · Cited by 82
Self-citationThe Alpha-Cell as Target for Type 2 Diabetes Therapy
Christensen, M., Bagger, J. I., Vilsboll, T., & Knop, F. K. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.369 · Cited by 65
“The suppression of glucagon is observed with both acute [103, 104] and chronic treatment [77, 91-102].”
BackgroundZhao, Y., Yang, L., Wang, X., & Zhou, Z. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2530 · Cited by 67
Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes
Bekiari, E., Rizava, C., Athanasiadou, E. A., Papatheodorou, K., Liakos, A., Karagiannis, T., Mainou, M., Rika, M., Boura, P., & Τσάπας, Α. (2015) · Endocrine · doi:10.1007/s12020-015-0841-1 · Cited by 71
Vardarli, I., Nauck, M. A., Köthe, L. D., Deacon, C. F., Holst, J. J., Schweizer, A., & Foley, J. E. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2178 · Cited by 61
“Because incretin hormones usually have low, basal concentrations in the fasting state and rapidly increase after nutrient ingestion (4, 6), DPP-4 inhibition supposedly has primarilypostprandial effects,withsomeadditionalglucoseloweringeffect in the fastingstate, and is therefore thought to act as an “incretin enhancer…”
BackgroundSelf-citationIncretin Hormone Secretion Over the Day
Åhrén, B., Carr, R. D., & Deacon, C. F. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00007-2 · Cited by 54
Effects of saxagliptin on β ‐cell stimulation and insulin secretion in patients with type 2 diabetes
Henry, R. R., Smith, S. R., Schwartz, S. L., Mudaliar, S. R., Deacon, C. F., Holst, J. J., Duan, R. Y., Chen, R. S., & List, J. F. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01417.x · Cited by 49
“Fewer studies have employed stepped clamp [17,19] or ramp [32] procedures to measure insulin response, such as trials with vildagliptin using glucose-insulin infusions.”
BackgroundLiu, Y., & Hong, T. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12128 · Cited by 50
“Furthermore, metformin increased the fasting active GLP-1 level in patients who had already received the DPP-4 inhibitor vildagliptin, and the level of active GLP-1 was positively related to the level of total GLP-1 [26].”
BackgroundDerosa, G., Ragonesi, P. D., Carbone, A., Fogari, E., Bianchi, L., Bonaventura, A., Romano, D., Cicero, A. F. G., & Maffioli, P. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0278 · Cited by 47
Dipeptidyl peptidase-4(DPP-4) inhibitors: promising new agents for autoimmune diabetes
Wang, X., Zheng, P., Huang, G., Yang, L., & Zhou, Z. (2018) · Clinical and Experimental Medicine · doi:10.1007/s10238-018-0519-0 · Cited by 51
Functional loss of pancreatic islets in type 2 diabetes: How can we halt it?
Marrano, N., Biondi, G., Cignarelli, A., Perrini, S., Laviola, L., Giorgino, F., & Natalicchio, A. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154304 · Cited by 41
Vildagliptin in clinical practice: a review of literature
Banerjee, M., Younis, N., & Soran, H. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903302265 · Cited by 38
“Such results have been reproduced using a smaller dose of 50 mg twice daily for a longer period of 12 weeks [27] and 52 weeks [28] in patients with T2DM.”
MethodIncretin Therapies: Effects Beyond Glycemic Control
Mudaliar, S. R. D., & Henry, R. R. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.014 · Cited by 38
Latent autoimmune diabetes in adults: a focus on β-cell protection and therapy
Yin, W., Luo, S., Xiao, Z., Zhang, Z., Liu, B., & Zhou, Z. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.959011 · Cited by 46
Katra, B., Klupa, T., SKUPIEN, J. K., Szopa, M., Nowak, N., Borowiec, M., Kozek, E., & Malecki, M. T. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0159 · Cited by 32
Wang, Z., Wang, J., Hu, J., Chen, Y., Dong, B., & Wang, Y. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119069 · Cited by 31
Hong, S., Park, C., Hwang, D., Han, K. A., Lee, C. B., Chung, C. H., Yoon, K., Mok, J., Park, K. S., & Park, S. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12870 · Cited by 29
Hong, S., Park, C. ‐., Han, K. A., Chung, C. H., Ku, B. J., Jang, H.-C., Ahn, C. W., Lee, M. ‐., Moon, M. K., Son, H. S., et al. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12631 · Cited by 27
Derosa, G., Ragonesi, P. D., Carbone, A., Fogari, E., D’Angelo, A., Cicero, A. F. G., & Maffioli, P. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.734499 · Cited by 28
“DPP-4 inhibitors, and in particular vildagliptin, have been reported to increase b-cell function as a result of improved sensitivity of b-cell to glucose [32,33], and improved ability of a-cells and b-cells to sense and respond to glucose after treatment [34].”
Preservation of Beta-Cell Function in Type 2 Diabetes
Nyalakonda, K., Sharma, T., & Ismail‐Beigi, F. (2010) · Endocrine Practice · doi:10.4158/ep10112.ra · Cited by 27
From Theory to Clinical Practice in the Use of GLP-1 Receptor Agonists and DPP-4 Inhibitors Therapy
Dicembrini, I., Pala, L., & Rotella, C. M. (2011) · Experimental Diabetes Research · doi:10.1155/2011/898913 · Cited by 26
“Vildagliptin improves islet function in T2DM under fasting conditions [55].”
BackgroundTargeted Therapies of the LKB1/AMPK Pathway for the Treatment of Insulin Resistance
Yamada, E., Lee, T.-W. A., Pessin, J. E., & Bastie, C. C. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.264 · Cited by 26
“For example, the αglucosidase inhibitors block glucose absorption in the gut; the sulphonylureas stimulate βcell insulin secretion; and the dipeptidyl peptidase 4 inhibitor increases insulin secretion by increasing GLP-1 and GIP levels, which inhibit glucagon secretion (2; 3).”
BackgroundProfile of vildagliptin in type 2 diabetes: efficacy, safety, and patient acceptability
Pan, C. Y., & Wang (2013) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s30071 · Cited by 28
Incretin-based therapies: new treatments for type 2 diabetes in the new millennium
Horowitz, M. (2009) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s4975 · Cited by 25
“111 Vildagliptin has been shown to increase insulin and C‑peptide responses to glucose by up to 100%, 108,112 suggesting improvements in β ‑cell function.”
Green, J. (2010) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s6270 · Cited by 22
Yang, L., Yuan, J., & Zhou, Z. (2014) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2014.01.008 · Cited by 25
“Vildagliptin (100 mg daily) has been shown to preserve beta-cell function in type 2 diabetes patients (76,77) and in subjects with impaired fasting glucose (78).”
Duvnjak, L. S., Blaslov, K., Lovrenčić, M. V., & Čuča, J. K. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.09.013 · Cited by 19
Hashim, M., Yokoi, N., Takahashi, H., Gheni, G., Oduori, O. S., Hayami, T., Murao, N., Hidaka, S., Minami, K., Mizoguchi, A., et al. (2018) · Diabetes · doi:10.2337/db17-1486 · Cited by 20
Bae, J., Kim, G., Lee, Y., Lee, B., Kang, E. S., & Soo, B. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0541-y · Cited by 18
Gray, S. M., Hoselton, A. L., Krishna, R., Slentz, C. A., & D’Alessio, D. A. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac396 · Cited by 16
Self-citationNam, T., Kim, A., & Oh, Y.-T. (2023) · Nutrients · doi:10.3390/nu15214556 · Cited by 29
“In fact, for diabetes patients, there is often a need for blood sugar and appetite regulation.”
BackgroundDPP‐4 inhibition and islet function
Åhrén, B. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2011.00184.x · Cited by 16
Prevention of Type 1 Diabetes: Past Experiences and Future Opportunities
Beik, P., Ciesielska, M., Kucza, M., Kurczewska, A., Kuźmińska, J., Maćkowiak, B., & Niechciał, E. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092805 · Cited by 18
Incretin Therapies: Effects Beyond Glycemic Control
Mudaliar, S. R. D., & Henry, R. R. (2009) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2009.05.010 · Cited by 20
Sjöstrand, M., Carlson, K., Arnqvist, H. J., Guðbjörnsdóttir, S., Landin‐Olsson, M., Lindmark, S., Nyström, L., Svensson, M. K. E., Eriksson, J. W., & Bolinder, J. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12116 · Cited by 19
Rajkumar, V., & Levine, S. N. (2021) · StatPearls · Cited by 29
Doesch, A. O., Gueler, I., Mueller, S., Helmschrott, M., Oeing, C. U., Frankenstein, Gleissner, Ruhparwar, Ehlermann, Dengler, et al. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s43092 · Cited by 19
Vich-Pérez, P., Abánades-Herranz, J. C., Navarro, G. M., Carrasco-Sayalero, Á., Salinero-Fort, M. Á., Sevilla-Machuca, I., Sanz-Pascual, M., Álvarez-Hernández-Cañizares, C., & de Burgos‐Lunar, C. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281657 · Cited by 14
Insights Into GLP-1 and GIP Actions Emerging From Vildagliptin Mechanism Studies in Man
Foley, J. E. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00780 · Cited by 13
Self-citationJi, L., Pan, C., Lu, J., Li, H., Li, Q., Li, Q., Peng, Y., Tian, H., Yao, C., Zhao, Z., et al. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-118 · Cited by 15
Åhrén, B. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13564 · Cited by 15
Metformin Combinatorial Therapy for Type 2 Diabetes Mellitus
Kupsal, K., Mudigonda, S., Sai, N. V. B. K., & Neelala, K. (2016) · Journal of Metabolic Syndrome · doi:10.4172/2167-0943.1000210 · Cited by 18
“In a VISION study in Chinese patients, the early use of combinatorial therapy of vidagliptin with ongoing metformin therapy achieved target glycemic goals and improves islet-cell function during fasting stage [37,38].”
BackgroundBeta‐cell function in type 2 diabetes ( T2DM ): Can it be preserved or enhanced?
Kassem, L. S., Rajpal, A., Barreiro, M. V. E., & Ismail‐Beigi, F. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13446 · Cited by 17
Xu, Y.-J., Pei, Y., Liu, Z., Tan, P., Liu, R., Chu, L., Ye, Z., Wang, W., & Wang, H. (2025) · Food Chemistry · doi:10.1016/j.foodchem.2025.143412 · Cited by 11
Su, Y., Su, Y., Lv, L., Wang, L., Li, Q., & Zhao, Z. (2014) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2014.1545 · Cited by 11
Li, A. P. Z., & Kariyawasam, D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00098-0 · Cited by 11
Elebrashy, I., Elkafrawy, N., Raouf, R., & Yousry, D. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108042 · Cited by 12
C-Peptide Levels Predict the Effectiveness of Dipeptidyl Peptidase-4 Inhibitor Therapy
Demir, Ş., Temizkan, Ş., & Sargın, M. (2016) · Journal of Diabetes Research · doi:10.1155/2016/4509603 · Cited by 9
“The authors reported that vildagliptin provided a significant reduction in HbA1c and increased acute insulin response as well as acute C-peptide response to glucose [10].”
BackgroundSuzuki, L., Kanazawa, A., Uzawa, H., Osonoi, Y., Masuyama, A., Azuma, K., Takeno, K., Takayanagi, N., Sato, J., Someya, Y., et al. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1404576 · Cited by 9
“A previous study showed that add-on vildagliptin therapy in patients with T2DM on metformin increased fasting GLP-1 (Glucagon-like peptide-1) levels, but not in patients controlled by diet alone [24].”
BackgroundNakamura, A., & Terauchi, Y. (2012) · Endocrine Journal · doi:10.1507/endocrj.ej12-0208 · Cited by 6
Chai, S., Zhang, R., Carr, R. D., Deacon, C. F., Zheng, Y., Rajpathak, S. N., Chen, J., & Yu, M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1203187 · Cited by 8
“Nine of them were crossover studies (11–13, 15, 16, 19, 21, 22, 24), while the remaining five studies (14, 17, 18, 20, 23) were parallel-group RCTs.”
BackgroundGheibi, S., Maleki, F., Safiri, S., Gouvarchinghaleh, H. E., Motlagh, B. M., & Hosseinpour, M. (2019) · Hepatitis Monthly · doi:10.5812/hepatmon.92199 · Cited by 5
Göke, R., Eschenbach, P., & Dütting, E. D. (2014) · Diabetes & Metabolism · doi:10.1016/j.diabet.2014.07.004 · Cited by 4
“Treatment with ildagliptin therefore leads to prolonged meal-induced increases n GLP-1 and GIP levels [4].”
Vildagliptin for the treatment of diabetes
Samraj, G. P. N. (2011) · Therapy · doi:10.2217/thy.11.75 · Cited by 4
Laorodphun, P., Chaisen, S., Amattat, S., Maphet, P., Printrakul, N., Pandith, H., Panya, A., Kongmali, B., Swe, M. T., & Arjinajarn, P. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1464463 · Cited by 4
Biological and Biosimilar Medicines in Contemporary Pharmacotherapy for Metabolic Syndrome
Górecka, W., Berezovska, D., Mrozińska, M., Nowicka, G., & Czerwińska, M. E. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17060768 · Cited by 2
“As a result, the action of incretin hormones is prolonged, promoting post-meal glucose regulation by increasing insulin secretion and reducing plasma glucagon levels [110].”
Hipoglicemia e tratamento da diabetes mellitus
Gonçalves, M. J. (2009) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 2
Otterbeck, P. E., & Banerji, M. A. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.6 · Cited by 1
Chang, J., Shin, J., Kim, H., Kim, K., Shin, J.-A., Yoon, K., Cha, B., Son, H., & Cho, J. (2013) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2013.37.1.72 · Cited by 2
“Vildagliptin improves glycemic control in type 2 diabetic subjects by increasing both α- and β-cell sensitivity to glucose [3-6] and decreases the risk of weight gain and hypoglycemia.”
BackgroundMonnier, L., Dejager, S., Sérusclat, P., Petit, C., Valensi, P. E., Huet, D., Raccah, D., Colette, C., Quéré, S., & Guerci, B. (2014) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(14)70840-5 · Cited by 2
“Cette augmentation est retrouvée de façon concordante dans de nombreuses études mécanistiques conduites avec la vildagliptine [11-15].”
BackgroundSelvaraj, V. (2025) · Cureus · doi:10.7759/cureus.91432 · Cited by 2
“Sitagliptin acts as a competitive inhibitor of DPP-4 enzyme, whereas vildagliptin functions as a substrate that forms a covalent complex with the catalytic site of DPP-4, leading to slow dissociation and sustained enzyme inhibition [3,5].”
Mistry, M., Lister, N., Andrews, C., Geransar, P., & Sinclair, A. J. (2011) · The British Journal of Diabetes · doi:10.1177/1474651411421500 · Cited by 1
The switch from insulin to vildagliptin in hemodialysis patients with diabetes
Kurokawa, Y., Iwata, Y., Kato, K., Kitajima, S., Takamura, T., Wada, T., & Koshino, Y. (2014) · Nihon Toseki Igakkai Zasshi · doi:10.4009/jsdt.47.539 · Cited by 1
Anfossi, G., Russo, I., Bonomo, K., & Trovati, M. (2010) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s3420 · Cited by 1
Vildagliptin in the Treatment of Type 2 Diabetes Mellitus
Florentiu, A., & Lichiardopol, R. (2013) · Romanian Journal of Diabetes Nutrition and Metabolic Diseases · doi:10.2478/rjdnmd-2013-0021
“The disposition index, a measure of insulin secretion corrected for the degree of insulin sensitivity, was significantly increased (by 80%) in a study in patients treated for 12 weeks with vildagliptin 50 mg bid [13].”
BackgroundEl efecto incretina y su participación en la diabetes mellitus tipo 2
Cuauhtémoc, C., & León, N. (2010)
SALEH, M. D. G. S. Y. H. S. A., GAAFAR, M. D. O. A. E.-M. A., & Metwally, E. M. (2018) · The Medical Journal of Cairo University/The Medical Journal of Cairo University · doi:10.21608/mjcu.2018.62824 · Cited by 1
Andreani, T., Silva, A. M., & de Souza, A. L. R. (2010) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Latent autoimmune diabetes in adults (LADA)
Pop, O. (2020) · Medic ro · doi:10.26416/med.135.3.2020.3238
Correia, C. P., Ferraz, R. V., Paulo, C., & Almeida, J. (2020) · Galicia Clínica · doi:10.22546/58/1980
Additional file 1 of Probiotics supplementation and insulin resistance: a systematic review
Salles, B. I. M., Cioffi, D., & Ferreira, S. R. G. (2020) · Figshare · doi:10.6084/m9.figshare.13225700
Zeng, W., Lv, C., Wang, J., Cai, S., Xu, J., Zeng, X., & Liang, Y. (2026) · Food Research International · doi:10.1016/j.foodres.2026.120110 · Cited by 1
Metadata
- Authors
- D'Alessio, D. A., Denney, A. M., Hermiller, L. M., Prigeon, R. L., Martin, J. M., Tharp, W. G., Saylan, M. L., He, Y., Dunning, B. E., Foley, J. E., & Pratley, R. E.
- Affiliations
- Department of Medicine (D.A.D., A.M.D., L.M.H.), University of Cincinnati and Cincinnati Veterans Affairs Medical Center, Cincinnati, Ohio 45267
- Cincinnati VA Medical Center (US)
- University of Maryland, Baltimore (US)
- University of Vermont (US)
- Clinical Research and Development (M.L.S.), Novartis Pharmaceuticals, East Hanover, New Jersey 07936
- Clinical Research and Development (Y.H., J.E.F.), Novartis Pharmaceuticals, Cambridge, Massachusetts 02139
- Pharmawrite (B.E.D.), Princeton New Jersey 08540
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2009-01-01
- Volume
- 94
- Issue
- 1
- Pages
- 81-88
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC2630874
- OpenAlex
- W1967477040
- Cited by
- 99
- References
- 39
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2 · 2023: 4 · 2022: 3 · 2021: 4 · 2020: 7 · 2019: 3 · 2018: 6 · 2017: 3 · 2016: 6 · 2015: 3 · 2014: 7 · 2013: 8 · 2012: 7
- FWCI
- 7.72
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- National Institute of Diabetes and Digestive and Kidney Diseases (DK57900, R01DK057900)
- National Center for Research Resources (M01 RR00109, M01RR000109, M01 RR 0808)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- vildagliptin, DPP-4 inhibitors, type 2 diabetes, insulin secretion, glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, incretins, C-peptide response, metformin, arginine stimulation, HbA1c
- MeSH terms
- Vildagliptin, Adamantane, Aged, Diabetes Mellitus, Type 2, Double-Blind Method, Fasting, Glycated Hemoglobin, Humans, Islets of Langerhans, Middle Aged, Nitriles, Pyrrolidines, Glucagon-Like Peptide 1, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.